(NASDAQ:DFLI),(NASDAQ:DFLIW), RENO, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage, today issued a Year-End Letter to Shareholders from its Chief Executive Officer and President, Dr. Denis Phares. Dear DFLI Shareholders, 2025 marked an important inflection point in Dragonfly Energy's […]

(CNSX:NIOB),(CNSX:NIOB.CN),(Boerse Frankfurt – Freiverkehr:IOR),(OTC US:NIOMF),(Other OTC:NIOMF), Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to provide an update on its Phase 1 soil-gas radon survey completed by RadonEx on the Company's Blanchette and

– Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA – Positioned U.S.-based biomanufacturing hub to supply genetic medicine products across North America, South America, Europe, Asia, and Australia – Added targeted insertion and epigenetic editing modalities to Life Edit's gene editing toolbox to expand diseases addressable through partnerships

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028 DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in patients

(NASDAQ:AVXL), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang

(NasdaqGM:VERA), BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company's management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San

(NasdaqGM:PFSA), Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of

(TSX-V:MD),(TSX-V:MD), MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Rio Tinto Exploration Canada Inc. (“RTEC“), is pleased to announce the results of the 2025 drilling campaign for lithium on the Galinee project. The Galinee project is located approximately 5 kilometres east of the Adina lithium deposit held

(TSX:GURU), MONTRÉAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada's leading organic energy drink brand1, will report its financial results for the fourth quarter and fiscal year ended October 31, 2025 on Thursday, January 22, 2026, before markets open. Management will hold a conference call to

(NASDAQ:ZVRA), CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on